IGF1 and neuroendocrine neoplasm: The type 2 receptor, SST2, is expressed in pituitary somatotrophic cells where it mediates the inhibition of growth hormone (GH) secretion, which in turn causes secretion of insulin-like growth factor 1 (IGF-1) from the liver and is also highly expressed in gut enteroendocrine and pancreatic islet cells, as well as neuroendocrine tumors that arise from these tissues [3].